



INOVA[®]

Heart and Vascular Institute

2018 INOVA ADVANCED HEART FAILURE SYMPOSIUM



©OVERCOME

SATURDAY, OCTOBER 13, 2018
Marriott Marquis, Washington DC

www.advancedhfsymposium.com



**Eugene
BRAUNWALD**

**KEYNOTE
SPEAKER**



**Robert
CALIFF**

**KEYNOTE
SPEAKER**



**Christopher
O'CONNOR**

**PROGRAM
CHAIR**



**Shashank
DESAI**

**PROGRAM
CO-DIRECTOR**

FACULTY

William Abraham, MD, FACC, FHSA
Professor of Medicine, Physiology, and Cell Biology
Director and Chair, Division of Cardiovascular Medicine
Associate Dean for Clinical Research
Director, Clinical Trials Management Office
Deputy Director, Davis Heart and Lung Research Institute
The Ohio State University

Tariq Ahmad, MD, FACC
Advanced Heart Failure and Transplant
Assistant Professor of Medicine
Yale New Haven Health System

Ana Barac, MD, PhD, FACC
Director, Cardio-Oncology program
Medical Director, Cardiac Rehabilitation program
MedStar Heart and Vascular Institute
Assistant Professor of Medicine
Georgetown University

Linda Bogar MD, FACC
Surgical Director of the Heart and Lung
Transplant Programs
Inova Heart & Vascular Institute

Eugene Braunwald, MD, MACC, FAHA, FESC
Distinguished Hersey Professor of Medicine
Harvard Medical School
Founding Chairman of the TIMI Study Group
Brigham and Women's Hospital

Michael Bristow, MD, PhD, FACC, FHSA
Professor of Medicine (Cardiology)
Director of Pharmacogenomics
University of Colorado Division of Cardiology
President and CEO
ARCA Biopharma

Javed Butler, MD, MPH, MBA, FACC, FHSA
Professor of Medicine
Patrick Lehan Chair, Cardiovascular Research
Chair, Department of Medicine
University of Mississippi

Robert Califf, MD, MACC, FAHA, FESC
Professor of Medicine
Vice-Chancellor for Health Data Science
Duke University
Senior Management Team, Verily Life Sciences
Former FDA Commissioner

Peter Carson, MD, FACC
Clinical Professor of Medicine
Georgetown University
Director, Heart Failure Program
Washington DC VA Medical Center

Lauren Cooper, MD, MHS, FACC
Director of Heart Failure Disease Management
Clinic
Associate Director of Heart Failure Research
Inova Heart & Vascular Institute

James Daubert, MD, FACC
Chief, Cardiac Electrophysiology
Professor of Medicine
Duke University

Shashank Desai, MD, FACC
Medical Director
Advanced Heart Failure and Transplant Program
Inova Heart & Vascular Institute

G. Michael Felker, MD, FACC, FHSA
Chief of the Heart Failure Section
Professor of Medicine
Duke University

Mona Fiuzat, PharmD, FACC, FHSA, FHFA
Former Sr. Scientific Advisor to FDA
Commissioner
Associate Professor of Medicine
Duke University
Executive Editor, JACC: Heart Failure

James Januzzi, MD, FACC
Hutter Family Professor of Medicine
Senior Cardiometabolic Faculty
Baim Institute for Clinical Research
Harvard Medical School

Marvin A. Konstam, MD, FACC, FHSA
Chief Physician Executive
The CardioVascular Center
Professor of Medicine
Tufts University School of Medicine

Harlan Krumholz, MD, SM, FACC, FAHA
Harold H. Hines, Jr. Professor of Medicine
Professor in the Institute for Social and Policy Studies
Director, Center for Outcomes Research and Evaluation
Yale University

**JoAnn Lindenfeld, MD, FACC, FAHA, FHSA Director, Heart
Failure and Transplant Program Professor of Medicine
Vanderbilt University**

Roxana Mehran, MD, FACC, FESC, FAHA
Professor of Medicine
Director, Interventional Cardiovascular Research and Clinical Trials
Zena and Michael A. Weiner Cardiovascular Institute
Mount Sinai School of Medicine

Alan B. Miller MD, FACC, FHSA
Professor of Medicine
University of Florida, Jacksonville

Christopher O'Connor, MD, MACC, FESC, FHSA
CEO and Executive Director
Inova Heart & Vascular Institute
Professor of Medicine
Duke University
Past HFSA President

Gurusher Panjra, MD, FACC, FAHA
Director, Heart Failure & Mechanical Circulatory Support Program
Associate Professor of Medicine
George Washington University School of Medicine

Mitchell Psofka, MD, PhD
Advanced Heart Failure, Transplant, and Pulmonary Hypertension
Associate Director Heart Failure Site Based Research and
Heart Failure Outreach Programs
Inova Heart & Vascular Institute

Joseph G. Rogers, MD, FACC, FHSA
Professor of Medicine, Division of Cardiology
Interim Chair, Department of Medicine
Duke University

Palak Shah, MD, MS, FACC, FHSA
Director, Cardiovascular Genomics Center
Director, Heart Failure Research
Inova Heart & Vascular Institute
Assistant Professor of Medicine
GW University

Ramesh Singh MD, FACS, FACC
Surgical Director of Mechanical Circulatory Support
Inova Heart & Vascular Institute

Alan Speir, MD, FACC
Director, Cardiothoracic Surgery
Inova Heart & Vascular Institute
Professor, Department of Surgery, Division of Cardiothoracic Surgery
Virginia Commonwealth University

Behnam Tehrani, MD, FACC, FSCAI
Medical Director, Cardiac Catheterization Laboratory
Inova Heart & Vascular Institute

Orly Vardeny, PharmD, MS, FHFSA
Associate Professor of Pharmacy and Medicine
University of Minnesota

Hector O. Ventura, MD, FACC, FACP
Section Head
Cardiomyopathy and Heart Transplantation
Ochsner Medical Center

Mary N. Walsh, MD, FACC, FHFSA
Medical Director, Heart Failure and Transplantation Director,
Nuclear Cardiology
St. Vincent Heart Center

David Whellan, MD, FACC, FHFSA
James C. Wilson Professor of Medicine
Associate Provost for Clinical Research
Associate Dean for Clinical Research
Executive Director, Jefferson Clinical Research Institute
Thomas Jefferson University

Clyde Yancy, MD, MACC, FAHA, FHFSA
Vice Dean for Diversity and Inclusion
Chief of Cardiology, Department of Medicine
Northwestern Feinberg School of Medicine

Program Description

The *Inova Heart and Vascular Institute 2018 Advanced Heart Failure Symposium* will provide a review of best practices in the field of heart failure, including current guidelines, co-morbidities with a particular emphasis on diabetes, innovative and novel pharmacological and technological treatment options and health policy concerns. The role of mechanical support, the differences in the types of devices, possible complications, and the latest thinking on home monitoring, surgical approaches and transplantation will be presented and discussed in detail, to help physicians to make better informed decisions regarding referral for transplant or mechanical cardiac support. Through interactive lectures, case studies and panel discussions, world renowned experts will present the very latest research and clinical trial results with an emphasis on the application to day to day clinical practice.

The program will cover the following general topics:

- Guideline Directed Medical Therapy and Novel Approaches to Heart Failure Management
- Cutting Edge Device Therapy for Heart Failure
- Treatment options for Advanced Heart Failure
- New insights on the Role of Biomarkers, Blood Pressure Targets and Cardio-oncology

Target Audience

The program is expected to draw 250 attendees, mostly physicians, from the mid-Atlantic region. The target audience consists of the following:

- Heart Failure specialists
- Cardiovascular clinicians
- Primary care physicians, hospitalists
- Fellows and residents in training
- Advanced practice nurses and other non-physician members of the cardiac care team

Educational Objectives

Upon completion of this course, participants should be able to:

- Understand and apply novel approaches and new pharmacological treatment options for the management of heart failure
- Utilize novel treatment devices for mitral regurgitation, sleep apnea, arrhythmias and sensors/monitoring devices appropriately
- Delineate the best practices for when to refer advanced heart failure patients for evaluation for heart transplant or mechanical cardiac support

CME Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the Joint Providership of the The University of Massachusetts Medical School and Inova Heart and Vascular Institute. The University of Massachusetts Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The University of Massachusetts Medical School designates this live activity for a maximum of 2 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only credit commensurate with the extent of their participation in the activity.



7:30 – 8:20 AM Registration, Coffee, Exhibits

7:55 – 8:25 AM **WHEN TO REFER FOR CRT OR VAD THERAPY: A CASE BASED APPROACH**
Opening Breakout Session: Sponsored by Medtronic

James Daubert, MD
Joseph Rogers, MD

8:25 – 8:30 AM **Opening Remarks**
Christopher M. O'Connor, MD
Shashank Desai, MD

8:30 – 9:10 AM OPENING KEYNOTE
ADVANCES IN HEART FAILURE: Cardiac and Renal Effects of SGLT2 Inhibitors in Diabetes
Eugene Braunwald, MD

PHARMACOLOGY: NOVEL APPROACHES TO DRUG THERAPY FOR HEART FAILURE

Session Moderator: Michael Bristow, MD, PhD

Panel Moderator: Mona Fiuzat, PharmD

9:15 – 9:25 AM **Current Management Strategies in HFpEF: The New Worldwide Epidemic**
Orly Vardeny, PharmD

9:25 – 9:35 AM **Should Race and Gender Affect Drug Therapy Decisions?**
Clyde Yancy, MD

9:35 – 9:45 AM **Beyond Diuretics – Anything Else for Symptom Relief?**
G. Michael Felker, MD

9:45 – 9:55 AM **Managing Hyperkalemia in Heart Failure Patients**
Lauren Cooper, MD

9:55 – 10:05 AM **Novel Therapies for Diabetes and Heart Failure**
Javed Butler, MD

10:05 – 10:15 AM **Treating Pulmonary Hypertension and RV Failure**
Mitchell Psootka, MD, PhD

10:15 – 10:35 AM **Clinical Cases and Panel Discussion (Moderator: Mona Fiuzat, PharmD)**
Orly Vardeny, PharmD – Clinical Case #1
Mitchell Psootka, MD, PhD – Clinical Case #2
Clyde Yancy, MD
G. Michael Felker, MD
Lauren Cooper, MD
Javed Butler, MD
Patient Representative

10:35 - 11:15 AM Exhibit and Networking Break, Posters

10:45 – 11:15 AM **UNDERSTANDING MITRAL REGURGITATION IN HEART FAILURE: A CASE BASED APPROACH**

Morning Breakout Session: Sponsored by Abbott

JoAnn Lindenfeld, MD
William Abraham, MD

**DEVICES: CUTTING EDGE DEVICE THERAPY FOR HEART FAILURE***Session Moderator: Alan Miller, MD**Panel Moderator: Peter Carson, MD*

11:20 – 11:30 AM Sensor Strategies for Heart Failure – Apple, Oranges and Bananas
David Whellan, MD

11:30 – 11:40 AM Ablation, ICD's and CRT for Heart Failure
James Daubert, MD

11:40 – 11:50 AM Sleep Apnea – To Treat or Not to Treat?
Christopher O'Connor, MD

11:50 AM – 12:00 PM Novel Device Therapies for HF
William Abraham, MD

12:00 – 12:10 PM Treating Mitral Regurgitation in HF
JoAnn Lindenfeld, MD

12:10 – 12:20 PM The Intersection of A. Fib and HF
Michael Bristow, MD, PhD

12:20 – 12:30 PM Patient Decisions about Device Therapy
Mary Walsh, MD

12:30 – 12:50 PM Clinical Cases and Panel Discussion (Moderator: Peter Carson, MD)
Mary Walsh, MD – Clinical Case #1
Alan Miller, MD – Clinical Case #2
David Whellan, MD
Michael Bristow, MD, PhD
JoAnn Lindenfeld, MD
Christopher O'Connor, MD
William Abraham, MD
James Daubert, MD

12:50 – 1:25 PM Lunch, Exhibits and Networking

1:05 – 1:20 PM Poster Session
Moderators / Judges: Lauren Cooper, MD; Mitch Psootka, MD; Palak Shah, MD;
Chris deFilippi, MD

1:30 – 2:15 PM LUNCH KEYNOTE SESSION

1:30 – 1:50 PM: THE FUTURE OF HEALTHCARE AND CV MEDICINE IN AMERICA
Robert Califf, MD

1:50 – 2:15 PM: PANEL

Moderator: Christopher M. O'Connor
Panelists: Robert Califf, MD;
Alan Speir, MD; Harlan Krumholz, MD

**DEBATES AND HEALTH POLICY***Session Moderator: Tariq Ahmad, MD**Panel Moderator: Christopher O'Connor, MD***DEBATE 1: CARDIO-ONCOLOGY: DOES LVEF MATTER?**

2:20 – 2:30 PM **LVEF Changes Should be Managed**
Ana Barac, MD

2:30 – 2:40 PM **No Clear Evidence**
Marvin Konstam, MD

DEBATE 2: SHOULD WE USE BIOMARKERS TO GUIDE THERAPY?

2:40 – 2:50 PM **Use Biomarkers to Guide Therapy**
James Januzzi, MD

2:50 – 3:00 PM **Guideline Directed, not Biomarker Guided**
Clyde Yancy, MD

DEBATE 3: HOW TO TREAT WOMEN: FROM THE EXPERTS

3:00 – 3:10 PM **Expert #1**
Roxana Mehran, MD

3:10 – 3:20 PM **Expert #2**
Hector Ventura, MD

3:20 – 3:40 PM **Panel Discussion (Moderator: Christopher O'Connor, MD)**
Roxana Mehran, MD
Hector Ventura, MD
Ana Barac, MD
Marvin Konstam, MD
James Januzzi, MD
Clyde Yancy, MD

3:40 – 3:55 PM Exhibits and Networking Coffee Break

**CUTTING EDGE CONCEPTS IN ADVANCED HEART FAILURE***Session Moderator: Gurusher Panjraht, MD**Panel Moderator: Shashank Desai, MD*

The University of Massachusetts Medical School designates this live activity for a maximum of 2 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only credit commensurate with the extent of their participation in the activity.

- 3:55 – 4:05 PM Palliative Care in End Stage Heart Failure: Symptom Management**
Joseph Rogers, MD
- 4:05 – 4:15 PM The New Allocation System: Who is Appropriate for Heart Transplant or Mechanical Support?**
Shashank Desai, MD
- 4:15 – 4:25 PM Novel Mechanical Support Devices in 2018**
Ramesh Singh, MD
- 4:25 – 4:35 PM Medical Management of LVAD patients for the Non-LVAD Specialist**
Tariq Ahmad, MD
- 4:35 – 4:45 PM Cutting Edge Concepts in Surgical Options**
Linda Bogar, MD
- 4:45 – 4:55 PM Improving Outcomes in Cardiogenic Shock**
Behnam Tehrani, MD
- 4:55 – 5:15 PM Clinical Cases and Panel Discussion (Moderator: Shashank Desai, MD)**
Palak Shah, MD – Clinical Case #1
Gurusher Panjraht, MD – Clinical Case #2
Joseph Rogers, MD
Christopher May, MD
Linda Bogar, MD
Ramesh Singh, MD

5:15– 5:30 PM Poster Awards, Raffle Winners, Closing Remarks – Christopher M. O'Connor

ENDORSED BY



SPONSORS & GRANTS

The INOVA Heart & Vascular Institute 2018 Advanced Heart Failure Symposium gratefully acknowledges the support of the following organizations and companies:

ULTIMATE SPONSORS

Medtronic



PLATINUM SPONSORS

Boston Scientific

Novartis

GOLD SPONSORS

Abiomed

Bayer

SILVER SPONSORS

Alnylam
Amgen

Atricure
CVRx

BRONZE SPONSORS

Boehringer Ingelheim
Edwards
Portola
Regeneron
ResMed
Sanofi

GRANTS

Abbott Diagnostics
Abiomed
Arbor Pharmaceuticals
AstraZeneca

Biotronik
Cytokinetics
Novartis

EXHIBITORS


Abbott
Abiomed
Actelion
Amgen
Alnylam
Atricure

Boehringer Ingelheim
Edwards
Grand Canyon University
Impulse Dynamics
Inova Heart & Vascular
Medtronic


Novartis
Otsuka
Pfizer
Portola
Regeneron/Sanofi

WHEN SHOULD YOU CONSIDER REFERRING FOR CRT OR VAD THERAPY?

Indicators of Patients* Who May Benefit from CRT¹



Indicators of Patients Who May Benefit from VAD Therapy



*On stable, optimal heart failure medical therapy if indicated.

These considerations are provided for general educational purposes only and should not be the exclusive source for this type of information. At all times, it is the professional responsibility of the practitioner to exercise independent clinical judgment in a particular situation.

Medtronic
Further, Together

References

- ¹ Yancy CW, et al. 2013 ACCF/AHA Guidelines for CRT. *J Am Coll Cardiol*. 2013;62:e147-239.
- ² Bardy GH, et al. *N Engl J Med*. 2005;352:225-237.
- ³ Moss AJ, et al. *N Engl J Med*. 2002;346:877-883.
- ⁴ Bristow MR, et al. *N Engl J Med*. 2004;350:2140-2150.
- ⁵ Cleland JG, et al. *Eur Heart J*. 2013;34:3547-3556.
- ⁶ Linde C, et al. *Eur J Heart Fail*. 2017;19:1056-1063.

- ⁷ Sweeney MO, et al. *Circulation*. 2003;107:2932-2937.
- ⁸ Curtis AB, et al. *N Engl J Med*. 2013;368:1585-1593.
- ⁹ Yancy CW, et al. 2017 ACC Expert Consensus Decision Pathway for Optimization of HF Treatment. *J Am Coll Cardiol*. 2018;71:201-230.
- ¹⁰ Davis MP, et al. *Am J Hosp Palliat Care*. 2005;22:211-222.
- ¹¹ Peura JL, et al. *Circulation*. 2012;126:2648-2667.

Medtronic, Medtronic logo, and Further, Together are trademarks of Medtronic. All other brands are trademarks of a Medtronic company.

UC201904534 EN ©2018 Medtronic. Minneapolis, MN. All Rights Reserved. Printed in USA. 09/2018

A person wearing a bright yellow shirt is sitting on a wooden suspension bridge that spans across a deep, narrow valley. The valley floor is a river with clear, light blue water. The surrounding mountains are rugged and covered in patches of snow and ice. The sky is filled with soft, colorful clouds, suggesting a sunrise or sunset. The foreground is a rocky, uneven path leading up to the bridge.

CARDIOVASCULAR. **COMMITTED.**

Photo on file at Abbott.
www.Vascular.Abbott
©2018 Abbott. All rights reserved.

The Abbott logo, which consists of a stylized white 'A' shape inside a white square frame, positioned above the word 'Abbott' in a bold, white, sans-serif font.

Abbott



Creating a healthier future.

Every day, we challenge ourselves to help people suffering from cardiovascular diseases.

Building on a heritage of 120 years of innovation, we are committed to prevention and treatment.

Together we are making a difference.



www.bayer.com



Boston Scientific
Advancing science for life™

IT TAKES COLLABORATION TO MAKE SCIENCE MORE TRANSFORMATIVE.

Everything it takes to advance science for life, we learn with you.

We share your passion to tackle the toughest healthcare challenges. It's why we work side-by-side with you, so we can better understand your clinical needs and work collaboratively to address them. We'll do everything it takes to deliver the innovative solutions that make a more meaningful difference in your patients' lives. This is the commitment behind every product, solution and relationship we build. It's what we do every day to advance science for patients, for life. To learn more about what it takes to advance science for life, visit www.bostonscientific.com

GENERAL INFORMATION

Venue

Marriott Marquis Washington, DC
901 Massachusetts Avenue NW
Washington, DC 2001
Liberty Ballroom M4
(4 Levels below the Lobby)

Parking

Hotel is valet only, metro rail is highly recommended

Time

Saturday, October 13, 2018
Registration, Coffee & Exhibits: 7:30AM
General Session Time: 8:25AM – 5:30PM

Contact Us

2018 Advanced HF Symposium Team
Phone: +1 (415) 839-8874
Email: advancedhf-oconnor@overcome.eu
inovaheartmeetings@inova.org